Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial
During APOLLO-B, outpatient worsening HF in patients with transthyretin amyloidosis with cardiomyopathy was frequent, prognostic, and reduced by patisiran.
Authors
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Matthew J. Maurer (ORCID: https://orcid.org/0000-0002-1867-0526)
- Shaun Bender (ORCID: https://orcid.org/0000-0002-7589-4534)
- Patrick Y. Jay (ORCID: https://orcid.org/0000-0001-9429-5492)
- Scott D Solomon
Institutions
- Brigham and Women's Hospital (US)
- Alnylam Pharmaceuticals (United States) (US)
- Columbia University Irving Medical Center (US)
- The Royal Free Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1016/j.jacc.2024.10.097
- Citations
- 7
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 5.64